Clinical Trial Update: Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of MN-001 (tipelukast) in idiopathic pulmonary fibrosis has completed enrollment; results detailing safety, tolerability, and efficacy have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• MN-001 (Tipelukast) (Tipelukast)

Snippet

Sponsor: MediciNova | Conditions: Idiopathic Pulmonary Fibrosis, IPF | Phase 2 | Status: COMPLETED | Results posted: 2026-01-23